The company intends to leverage its ultra-high-throughput screening platform to analyze billions of candidate sequences. By integrating proprietary AI-design optimization, the research team seeks to identify and validate elements that can be licensed to pharmaceutical partners to enhance the performance of genetic medicines. Principal Investigator Patrik Engström, Ph.D., emphasized that noncoding sequences serve as vital control points for protein expression, making them a high-value target for therapeutic refinement.

This federal funding supports the initiative titled "Enhanced nucleic acid therapeutics: synthetic sequence elements for boosting protein expression in genetic medicines" under award number 1R44TR006096-01. According to CEO Drew Burch, the grant reinforces the firm’s strategy of developing enabling technologies that address persistent manufacturing and design gaps in the biotechnology industry. The project marks a transition from foundational research into a phase focused on creating scalable, validated tools for broader commercial application in the genetic medicine market.